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Summary 
Purpose: To investigate patient-doctor agreement on clinical trial discussion cross-
culturally. Methods: In the International Breast Cancer Study Group Trial 33-03 on 
shared decision-making for early breast cancer in Australian/New Zealand (ANZ) and 
Swiss/German/Austrian (SGA) centers, doctor and patient characteristics plus doctor 
stress and burnout were assessed. Within two weeks post-consultation about 
treatment options, the doctor and patient reported independently, whether a trial was 
discussed. Odds ratios of agreement for covariables were estimated by generalized 
estimating equations for each language cohort, with doctor as random effect. 
Results: In ANZ, 21 doctors and 339 patients were eligible; in SGA, 41 doctors and 
427 patients. In cases where the doctor indicated “no trial discussed,” 82% of both 
ANZ and SGA patients agreed; if the doctor indicated “trial discussed,” 50% of ANZ 
and 38% of SGA patients agreed, respectively. Factors associated with higher 
agreement were: low tumor grade and fewer patients recruited into clinical trials in 
SGA; public institution, patient born in ANZ (vs. other), higher doctor 
depersonalization and personal accomplishment in ANZ. Conclusion: There is 
discordance between oncologists and their patients regarding clinical trial discussion, 
particularly when the doctor indicates a trial was discussed. Factors contributing to 
this agreement vary by culture. (200 words) 
 
Key words 
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Introduction 
Clinical trial discussions are challenging for both patients and doctors. Patient 
understanding of trial issues is poor.1 Many patients have negative attitudes to trials, 
which may potentially compromise informed consent. These attitudes are a key issue 
to be addressed by doctors.2 Both patients and doctors may be concerned about 
further issues, such as the admission of medical uncertainty or the relocation of the 
treatment decision from the doctor-patient relationship to computerized random 
assignment.3 Doctors may be reluctant to present the option of a trial to patients. 
Albrecht et al. reported on two urban, National Cancer Institute-designated 
comprehensive cancer centers, where only a minority (20%) of potentially eligible 
patients was explicitly offered a trial. When offered a trial, most patients (75%) 
agreed to participate.4 
 
In trial discussions, the quality and quantity of communication between the 
oncologist, patient, and family or companion are important to the patient's decision-
making process.4 The role of emotions regarding trial participation has rarely been 
investigated.5,6 In elderly cancer patients, the type of nurses’ response to their 
emotions has been shown to impact on information recall.7 Whether such factors 
influence patients’ decision-making is not known. One fundamental indication of 
whether information about trials has been adequately clear is whether there is 
agreement between the patient and the doctor on whether they discussed a trial at 
all. Disagreement on trial discussions may compromise informed consent. Further, if 
we can identify factors associated with such agreement we may be able to identify 
patient and doctor characteristics indicative of a need for greater care in explaining 
trials. This information may help tailor training in trial discussion for doctors. 
 
Our objective was to cross-culturally examine agreement between patients with early 
breast cancer and their doctors regarding whether a trial discussion had taken place 
in consultations about adjuvant therapy. These consultations were studied within an 
international randomized controlled trial of a communication skills training to increase 
the quality of shared decision-making.8 We investigated factors related to patients, 
doctors and the local setting associated with patient-doctor agreement on trial 
discussion, and the association between patient-doctor agreement and patient 
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decision outcomes. In a subsample, we explored the association between this 
agreement and cognitive and emotional aspects of decision-making. 
 
Patients, Doctors and Methods 
The International Breast Cancer Study Group (IBCSG) conducted Trial 33-03 in 
centers in Australia and New Zealand (referred to as ANZ), and Switzerland, 
Germany and Austria (referred to as SGA), with the doctor as the unit of block 
randomization after stratification for center. The training consisted of a seven-hour 
interactive workshop with 1-2 follow-up telephone calls over two months. The 
elements of this training were evidence-based,9 incorporating presentation of 
principles,10 a video modelling ideal behaviour and role-play practice focusing on four 
key concepts: ensuring a shared decision-making framework; structuring information 
into a sequence or order; ensuring the inclusion of different, specific types of 
information in a clear manner; considering the disclosure of specific controversial 
information and avoiding coercive communication.10 The details are described 
elsewhere.8 The ethics committees of all participating centers (Appendix) approved 
the protocol. 
 
Medical, surgical, radiation and gynaecological oncologists, involved in the treatment 
of patients with early breast cancer at major cancer centers or clinics (including 
private oncologists), and their patients for whom adjuvant therapy for breast cancer 
was indicated, were eligible. The following additional patient criteria were required: 
lower age limit of 18 years, adequate knowledge of the local language (English or 
German), and being mentally and physically capable of participating. Doctor 
participation was independent of previous or concurrent participation in other types of 
communication training. 
 
Procedures and measures 
After giving informed consent, doctors at participating centers were enrolled 
concurrently. Following baseline assessment and before the scheduled training 
workshop, they were randomly assigned to the experimental (training workshop) or 
control (no training workshop) group. Patients of enrolled doctors were recruited 
before their doctors were randomized (pre-randomization cohort) and after the 
workshop, if assigned, or at an equivalent time-point, if not assigned (post-
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randomization cohort). Local staff identified eligible patients within a flexible time 
window of approximately 12 months in each randomization cohort. For each doctor, 
5-10 patients were to be enrolled in the pre- and 8 or more in the post-randomization 
cohorts. 
 
Trial outcomes were selected based on studies that evaluated decision aids 
designed to facilitate shared decision-making.11 Two weeks before their initial 
consultation discussing treatment options, patients gave informed consent and 
completed a baseline questionnaire gathering demographics and self-report 
measures including state anxiety by Spielberger12. 
 
Two weeks after the consultation, patients were mailed a questionnaire with a pre-
paid, addressed return envelope. In addition to the baseline measures, patients were 
asked whether a trial discussion had taken place in their consultation, besides other 
disease and treatment factors. The questionnaire further included measures of 
satisfaction with: a) decision13; b) consultation (adapted from Roter14 and Korsch et 
al15); and c) doctor communication regarding standard treatment options9 and clinical 
trials9; plus decisional conflict16. Patient measures were in English for ANZ and 
German for SGA centers. Prior to randomization doctors completed the Maslach 
Burnout Inventory (3 subscales: depersonalization, emotional exhaustion, and 
personal accomplishment) as used by Ramirez17 in English. 
 
Further information was obtained within each language cohort. In ANZ centers, 
cognitive and emotional aspects of shared decision-making were coded in a 
subsample of audio-taped consultations, using the OPTION scale18, the RECC 
coding system19 and a rating for doctor blocking and facilitating behavior20. In SGA 
centers, the doctors recorded the duration of each consultation. 
 
Statistical analysis 
We investigated factors associated with agreement between patients and their 
doctors regarding whether or not a trial was discussed. The primary endpoint, 
patient-doctor agreement, was defined at the patient level. Patients were 
dichotomized into those who agreed with their doctor about whether a trial had been 
discussed (agreement) and those who did not agree. Given the explorative nature of 
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this investigation, we chose a conservative approach to missingness: when either the 
doctor or the patient reported missing information for trial discussion, the patient was 
considered not to have agreement with her doctor. When both had missing 
information for trial discussion, patient-doctor agreement was considered missing, 
and the patient was excluded from the analysis. For reasons of consistency, we 
examined the proportion of agreement also in the subgroup of pairs without missing 
information. All analyses were presented separately by language cohort. 
 
Baseline characteristics of doctors and patients were reported. Trial discussion 
responses were cross-tabulated by patients and their doctors. Odds ratios of patient-
doctor agreement for selected covariables were estimated by generalized estimated 
equations (GEE), with doctor as a random effect. GEE was used to account for the 
clustering of patients within doctor and to ensure that the variability of parameter 
estimates and testing accounted for this effect. To determine which of the doctor and 
patient characteristics were to be considered in the models, two-sided Fisher’s exact 
test was used to compare categorical variables between patient-doctor agreement 
groups, and two-sided Wilcoxon Rank-Sum test was used to compare continuous 
variables between these groups. Both the Fisher’s exact test and the Wilcoxon Rank-
Sum test assume independence of patients. Results from the Fisher’s exact tests and 
Wilcoxon Rank-Sum tests were considered, and doctor and patient characteristics 
that differed between patient-doctor agreement groups were included in the initial 
model. Stepwise selection was used to determine the best GEE fit model. Odds 
ratios, standard errors, and 95% Confidence Intervals (CIs) of the covariates are 
reported. No alpha-adjustments were made because we intend our findings to be 
hypothesis-generating and therefore descriptive only, and p-values should be 
regarded as such. 
 
Results 
Sample description and patient characteristics 
For the present analysis, 769 patients from 62 doctors were eligible. For three 
patients, both doctor and patient data regarding discussion of a trial were missing, 
leaving 766 patients. Ten patients had missing doctor assessments, and 65 patients 
had missing patient assessments. The doctors documented that a trial was available 
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in 68 patients (20%) from the ANZ cohort and in 150 (35%) from SGA cohort, 
respectively. 
 
The baseline characteristics of eligible doctors are shown in Table 1. They were 
balanced between randomization arms. With a few exceptions, the baseline 
characteristics of eligible patients of these doctors were also balanced between 
randomization arms (Table 2, randomization arms not shown).  
 
Patient-Doctor Agreement 
The patient-doctor agreement on trial discussion is summarized in Table 3. These 
numbers do not account for the effect of multiple patients per doctor. The overall 
proportion of concordant responses regarding whether or not a clinical trial was 
discussed was 75% for ANZ and 66% for SGA. In patients without missing data, the 
corresponding proportions were 84% for ANZ and 72% for SGA. 
 
In cases where the doctor indicated “trial not discussed,” 82% of both ANZ and SGA 
patients agreed. In those cases where the doctor indicated “trial discussed,” the 
agreement was lower, with 50% and 38% of ANZ and SGA patients agreeing, 
respectively. These findings were consistent in patients without missing data. 
 
Predictors for patient-doctor agreement 
The predictors for patient-doctor agreement in our GEE model are summarized in 
Table 4. In the ANZ cohort, treatment in a public institution was associated with better 
agreement (P<0.0001). Patients born in New Zealand (vs. other; P=0.0004) and 
Australia (vs. other; P=0.09) showed better agreement. Doctors who indicated more 
personal accomplishment had better agreement P<0.0001). Those who indicated 
more depersonalization showed a marginal although statistically significant 
association with better agreement (P=0.01). 
 
In the SGA cohort, a lower tumor grade was associated with better agreement (grade 
1 vs 2: p=0.002; grade 1 vs 3: P<0.0001). Those doctors who recruited less patients 
into clinical trials had better agreement with their patients (P=0.03). When looking at 
percentages of patients, more patients with positive hormone receptor status, less 
positive lymph nodes, and less anxiety had better agreement, and patients’ country 
8 
 
of birth and education were associated with agreement; however, these effects were 
no longer significant when accounting for multiple patients per doctor. 
 
The remaining patient and doctor characteristics (Tables 1 and 2) were not 
associated with patient-doctor agreement in either cohort. In particular, there was no 
indication that agreement was influenced by the randomized communication 
intervention. The negative effect of a higher number of patients recruited into clinical 
trials by the participating doctors was not driven by those doctors recruiting no 
patients to clinical trials or by the number of patients the doctors enrolled into the 
present trial. A separate investigation of predictors according to agreement on “trial 
discussed” and “not discussed” showed little variation and was consistent overall 
(data not shown). 
 
Patient-doctor agreement and patient decision outcomes 
The association between patient-doctor agreement and patient decision outcomes 
 (i.e., decisional conflict, satisfaction with decision, satisfaction with consultation, 
satisfaction with doctor communication overall and regarding a clinical trial) was 
investigated. Whether patients agreed or not with their doctors on trial discussion was 
not associated with patient decision outcomes in the ANZ or SGA cohort (data not 
shown). 
 
Further explorative analyses 
In the ANZ cohort, we explored cognitive and emotional aspects of shared decision-
making based on blind interview ratings. Quantitative and qualitative data were 
available from 70 audio-taped consultations. After removing cases with incomplete 
transcripts (due to recording problems), or insufficient patient data (due to non-return 
of questionnaires), a total of 55 consultations from 20 doctors were assessable. No 
differences in demographics or patient outcomes were found between the 55 
complete cases and the 12 cases with incomplete data. 
 
A higher total number of emotional cues and concerns in the consultation (initiated 
either by the patient or doctor) was associated with less patient-doctor agreement 
(P=0.04; Table 5). A higher average level of the doctors’ empathy in response to all 
cues and concerns showed a tendency in the same direction, with less empathy 
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being associated with better agreement (P=0.09). Of note, neither the doctors’ level 
of behavior exhibiting competent shared decision making (OPTION) nor blocking or 
facilitating behavior were associated with patient-doctor agreement. 
 
In the SGA cohort, the association between the duration of the consultation and 
patient-doctor agreement was explored. The median duration was 40 minutes 
(N=415, range: 15-125). There was moderate variation among Austrian, German and 
Swiss centers with a median (range) of 30 (15-90), 35 (15-125), and 60 (30-100) 
minutes, respectively. There was no association between duration of consultation 
and agreement. 
 
Discussion 
Two weeks after their consultation, a moderate percentage of doctors and their 
patients with early breast cancer were in agreement on whether or not they had 
discussed a clinical trial. Agreement includes the components of both “discussed” 
and “not discussed”. The agreement between doctors and patients was good on “trial 
not discussed” but poor on “trial discussed”. Thus, if a trial was introduced into the 
discussion as a real option, the recollection of this discussion clearly diverged 
between patients and their doctors. This observation was consistent between the 
ANZ and the SGA cohorts. It is suggestive of a selective patient perception that 
clinical trials are not discussed. Many patients may have perceived a trial as less 
important in this particular situation. Based on this assumption, we would expect an 
impact of patient-doctor agreement on actual decision-making. 
 
Factors predicting patient-doctor agreement were not consistent between the ANZ 
and the SGA cohorts. In SGA, poorer prognostic factors and in particular a high 
tumor grade were associated with poorer agreement, perhaps because these factors 
made the trial discussion more demanding. It is possible that patients struggling with 
the bad news of a poor prognosis may have heard, understood and recalled less of 
the consultation.21 Less patients recruited into clinical trials by the doctor was also 
associated with better agreement in SGA only. Enrolling patients on a routine basis 
does not imply an increase in agreement. The reason for this unexpected finding was 
not determined by those doctors recruiting no patients into trials and, therefore, 
remains unclear.  
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The doctors’ perceived personal accomplishment was associated with better 
agreement in ANZ only, as was treatment in a public institution and being born in the 
country of recruitment. It is possible that doctors who explain trials more clearly 
achieve not only greater agreement with their patients but also feel a greater sense 
of personal accomplishment. Patients not born in the country of recruitment, perhaps 
struggling with cultural and language differences, may find it harder to understand 
what their doctor is saying, including information about clinical trials.22 The 
differences between ANZ and SGA in factors associated with agreement point to the 
critical impact of cultural factors and the local setting, whereas doctor gender, age or 
the years of professional experience, and patient age were not related to agreement 
in either cohort. 
 
In the ANZ cohort we explored the doctors’ shared decision-making behavior and its 
association with agreement. It is important to note that this analysis was restricted to 
a selected and underpowered subsample for investigating multiple predictors by our 
GEE model. The less emotional cues and psychosocial concerns were emitted in the 
consultation, the higher the agreement on trial discussion. Doctors’ empathy, a key 
communication skill, appeared to be rather hindering for this particular outcome. It is 
possible that with greater emotion present, patients were less able to focus on the 
discussion and recall what was said later. The patients who emitted more cues and 
concerns, and subsequently received more empathy, were more distressed. This has 
been shown to limit information recall.23 Cognitive and emotional aspects of shared 
decision-making have different effects on various patient outcomes, as previously 
suggested in this subsample.24  
 
Agreement on trial discussions is likely to be higher if information provision is clearer. 
Clarity is enabled by short information units provided in a clear and explicit structure. 
Interestingly, since the duration of the consultation was not associated with 
agreement in the SGA cohort, simply talking longer does not appear to result in 
greater clarity and therefore greater agreement. 
 
Our communication training did not affect patient-doctor agreement. A more targeted 
and intensive training is needed to ensure that clinicians are able to tailor their 
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consultations to their patients’ information needs about treatment options and clinical 
trials. Elwyn et al have summarized the main conditions for shared decision-making 
to become part of mainstream clinical practice: ready access to evidence-based 
information about treatment options; guidance on how to weigh up the pros and cons 
of different options; and a supportive clinical culture that facilitates patient 
engagement.25 We feel that these conditions are similarly significant for trial 
discussions. The impact of these conditions may be moderated by selected patient 
and doctor characteristics as suggested by our findings. As discussed elsewhere, we 
propose interventions more specifically adapted to local needs with individual follow-
up based on real-time supervision of the doctors’ communication with their patients.8 
Skills uptake may be improved by practicing trial discussions related to a specific trial 
currently recruiting in the center. 
 
Overall, our findings confirm that there is substantial discordance between 
oncologists and their breast cancer patients on treatment information conveyed and 
received. 26 Similar findings were reported in lung27 and other cancer patients. Our 
study shows that this is true for clinical trial discussions also.28 
 
Several limitations have to be considered. Although the question on trial discussion 
has obvious face validity, it would need to be defined more exactly for a further 
investigation. For the particular setting of phase I trial discussions, Jenkins et al 
pointed recently to the omissions of important information, such as prognosis.29 
Audio recording as independent reference material, and thus a comprehensive 
analysis of concordance,27,30 was not feasible for our total sample. We have no 
information on whether patients received study information (handout with trial 
description, web-link, consent form), which may impact on patients’ recollection of 
trial discussions. Finally, whether the doctors were more reluctant to clearly address 
the option of a trial because they felt monitored on their communication cannot be 
excluded. 
 
In conclusion, there is discordance between oncologists and their patients regarding 
clinical trial discussion, particularly when the doctor indicates a trial was discussed. In 
contrast to well established international standards of clinical trial methodology, the 
discussion about trials is also related to the local setting and to cultural factors. These 
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issues are relevant for communication skills training and have not received sufficient 
attention in studies on decision-making in oncology. (3000 words) 
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Table 1: 
Baseline characteristics for eligible doctors by culture 
 Australia/New Zealand 
Switzerland/Germany/ 
Austria 
 N % N % 
N 21 100 41 100 
Gender     
Male 11 52 15 37 
Female 10 48 26 63 
Specialty     
Medical Oncology 12 57 11 27 
Radiology  6 29 - - 
Surgeon 3 14 4 10 
Gynaecologist - - 26 63 
Institution     
Public  14 67 40 98 
Private - - - - 
Both 7 33 - - 
Previous training in communication skills 11 52 10 24 
        
 med (range) med (range) 
Age, median (range) 46 (33,  62) 34 (24,  48) 
Previous years of practice, median (range) 19 (2, 37) 6 (1, 24) 
Ave. number of patients per doctor recruited 
to trials over 6 months, median (range)* 
10 (3, 50) 15 (3, 200) 
Burnout**     
Depression 21.3 (0, 55.3) 21.3 (0, 76.5) 
Emotional Exhaustion 28.9 (5.8, 62.1) 23.8 (7.2, 65) 
Personal Accomplishment 76 (40, 84) 68 (36, 84) 
 
*refers to any trial, 6 SGA doctors have missing recruitment information 
**9 SGA doctors have missing burnout information 
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Table 2: 
Patient baseline characteristics by culture, for assessable patients 
 Australia/New Zealand  
Switzerland/Germany/ 
Austria 
 N % N % 
N 339 100 427 100 
Stage of Tumor     
Missing 8 2 10 2 
Localized (node negative) 196 58 267 63 
Advanced (node positive) 135 40 150 35 
Number of Nodes     
Missing 8 2 10 2 
0 196 58 267 63 
1-3 85 25 73 17 
4-10 27 8 44 10 
>10 8 2 12 3 
Unknown 15 4 21 5 
Grade of tumor     
Missing 16 5 11 3 
1 68 20 58 14 
2 142 42 184 43 
3 113 33 174 41 
Hormone receptor status     
Missing - - - - 
Negative 77 23 78 18 
Positive 218 64 328 77 
Unclear at time of consultation 39 12 15 4 
Country of birth     
Missing - - 14 3 
Australia   161 47 - - 
New Zealand   78 23 - - 
Switzerland - - 90 21 
Germany - - 165 39 
Austria - - 105 25 
Other 99 29 52 12 
Language     
Missing - - 5 1 
English 307 91 3 1 
German - - 380 89 
French - - 3 1 
Italian - - 7 2 
Other 31 9 29 7 
18 
 
 Australia/New Zealand  
Switzerland/Germany/ 
Austria 
 N % N % 
Medical Training 73 22 66 15 
Education     
Missing 9 3 16 4 
Did not graduate HS or equivalent   109 32 165 39 
HS diploma or equivalent   135 40 182 43 
University degree   57 17 59 14 
Graduate degree   29 9 5 1 
 med (range) med (range) 
Age, median (range) 52 (27, 83) 58 (24, 88) 
Tumor size, median (range) 2 (0.1, 40) 2 (0, 12) 
Anxiety**, median (range) 44 (20, 80) 45 (20, 78) 
 
**Anxiety was measured pre-consultation 
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Table 3: 
Cross tabulations of patient-doctor agreement information on trial being 
discussed by language cohort, for all patients 
 
ANZ Patient(below)\ Doctor (right) Missing Trial not discussed Trial discussed Total 
 Missing - 26 7 33 
 Trial not discussed 3 219 27 249 
 Trial discussed 1 22 34 57 
 Total 4 267 68 339** 
 
SGA Patient(below)\ Doctor (right) Missing Trial not discussed Trial discussed Total 
 Missing - 24 8 32 
 Trial not discussed 4 225 84 313 
 Trial discussed 2 24 56 82 
 Total 6 273 148 427* 
 
*Excludes 2 patients with both doctor and patient assessments missing  
**Excludes 1 patient with both doctor and patient assessments missing  
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Table 4: 
Odds ratios for patient-doctor agreement vs disagreement. Generalized 
Estimated Equations by language cohort for eligible doctors and their 
assessable patients* 
 
Cohort Variable* 
Odds 
Ratio 
Standard 
Error 
Lower 
Confidence 
Limit 
Upper 
Confidence 
Limit P-value 
ANZ Public only vs. Private/Public 
institute 3.67 1.17 1.96 6.86 
<.0001 
 Born in Australia vs. Other 1.58 0.43 0.92 2.68 0.09 
 Born in New Zealand vs. Other 3.01 0.94 1.64 5.56 0.0004 
 Doctor burnout, depersonalization┼ 1.03 0.01 1.01 1.05 0.01 
 Doctor burnout, personal 
accomplishment┼ 1.04 0.01 1.02 1.06 <.0001 
SGA Tumor Grade 1 vs. 2 2.98 1.06 1.48 5.99 0.002 
 Tumor Grade 1 vs. 3 3.65 1.18 1.94 6.88 <.0001 
 Ave. num. of patients per doctor 
recruited to trials over 6 months: 
≤5pts vs. >5pt 
2.01 0.64 1.08 3.76 0.03 
* Accounting for randomization group and pre- or post-randomization cohort 
┼ For Doctor burnout variables, depersonalization and personal accomplishment, higher scores 
correspond to higher degrees of experienced burnout. Thus, an odds ratio >1 indicates that the odds 
of agreement increase when the average response score increases by one unit [Doctor 
depersonalization range: 0 – 102; Doctor personal accomplishment range: 0 – 84]. 
Note: The ANZ cohort includes 21 doctors and 339 patients. The SGA cohort includes 41 doctors and 
427 patients. 
 
. 
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Table 5: 
Odds ratios for patient-doctor agreement vs. not, Generalized Estimated 
Equations for assessable ANZ audio-taped consultation participants only, five 
separate models* 
 
Model* Variable in Model* 
Odds 
Ratio 
Standard 
Error 
Lower 
Confidence 
Limit 
Upper 
Confidence 
Limit P-value 
OPTION Observing Patient Involvement scale┼ 0.95 0.037 0.88 1.02 0.17 
RECC (a) Total number of Emotional cues and 
concerns┼┼ 
0.83 0.079 0.69 1.00 0.04 
RECC (b) Ave. level of empathy expressed across 
all cues┼┼ 
0.26 0.206 0.05 1.23 0.09 
Blocking Blocking Behavior      
 High vs. Low 3.41 3.081 0.58 20.03 0.17 
 High vs. Med 1.36 1.097 0.28 6.60 0.70 
 Med vs. Low 2.50 2.028 0.51 12.26 0.26 
Facilitating Facilitating Behavior      
 High vs. Low 1.66 1.580 0.26 10.72 0.59 
 High vs. Med 0.75 0.492 0.20 2.72 0.66 
 Med vs. Low 2.23 1.670 0.51 9.68 0.29 
*Each model accounts for randomization group and pre- or post-randomization cohort and doctor as a 
random effect 
┼ For the variable, OPTION, higher scores correspond to a higher level of behavior exhibiting the 
competencies of share decision making; thus, an odds ratio <1 indicates that the odds of agreement 
decrease when the average response score increases by one unit [OPTION scale: 0 - 100] 
┼┼ For the variables, RECC (a), and RECC (b), higher scores correspond to a higher level of empathy 
provision to cues/concerns; thus, an odds ratio <1 indicates that the odds of agreement decrease 
when the average response score increases by one unit [RECC scale: 0-3] 
Note: The ANZ audio-taped consultation cohort includes 20 doctors and 55 patients. 
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APPENDIX OF PARTICIPATING CENTERS, DOCTORS AND LOCAL 
COORDINATORS 
Australia 
St Vincents Hospital, Melbourne: R. Snyder, W. Burns, A. Dowling, Nadia Ranieri 
Maroondah Hospital, Maroondah: J. Chirgwin, Suzanne Giddings 
Royal Prince Alfred Hospital, Sydney: S. Pendlebury, J. Beith, A. Hamilton, Gina Bark 
Sir Charles Gairdner Hospital, Perth: C. Saunders, L. Jackson, N. Spry, F. Cameron, 
M. Taylor, R. Chee, Anna Davies, Philippa Kelly 
Flinders Medical Center, Adelaide: B. Koczwara, Alison Richards 
Westmead Hospital Sydney: V. Ahern, P. Harnett, Mary Cooper 
Nepean Cancer Care Center, Penrith: N. Wilcken, Penny Murie 
New Zealand 
Auckland Hospital, Auckland: P. Thompson, V. Harvey, Joline Ong 
Waikato Hospital, Hamilton: I. Campbell, Jenni Scarlet 
Dunedin Hospital, Dunedin: D. Perez, Alison Wylie 
Switzerland 
Kantonsspital St. Gallen: B. Thürlimann, A. Casty, M. Hoefliger, A. Müller 
Inselspital Bern: S. Aebi, M. Rabaglio, C. Baumann 
Germany 
Universitätsklinik Frankfurt: M. Liszka, S. Loibl, K. Schmidt, V. Gies, H. Trümper 
Frauenklinik Technische Universität München: K. Miska, U. Euler, D. Paepke, K. 
Gauger, A. Baumgärtner 
Universitätsfrauenklinik Kiel: C. Crohns, I. Meinhold-Heerlein, A. Ulrich, S. Grebe, J. 
Haller, A. Lüesse, J. Dürkop 
Krankenhaus München Schwabing: Andrea Schulte, Alexandra von Holle, Sabine 
Schmid 
Universitätsklinikum Jena: O. Camara, J. Hermann, A. Egbe, A. Kavallaris, H. 
Winzer, B. Härtwig, S. Krauspe 
Austria 
Wilhelminenspital Wien: H. Lass, T. Scholl, M. Brunbauer M. Riegler-Keil 
Allgemeines Krankenhaus Wien: C. Singer, Y. Yücel, D. Gschwantler-Kaulich, A. 
Fink-Retter, D. Bikas, M. Tea 
Landeskrankenhaus Feldkirch: M. Knauer, R. Köberle-Wührer, P. Elke 
 
